ANI Pharmaceuticals (NASDAQ:ANIP) was downgraded by investment analysts at TheStreet from a “b” rating to a “c+” rating in a report issued on Tuesday.
Other research analysts also recently issued research reports about the stock. Zacks Investment Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating and set a $71.00 price objective on the stock in a report on Tuesday, November 7th. ValuEngine upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, November 4th. Canaccord Genuity reissued a “buy” rating on shares of ANI Pharmaceuticals in a research note on Thursday, November 2nd. Finally, BidaskClub raised shares of ANI Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, January 5th. One research analyst has rated the stock with a sell rating, three have given a hold rating and two have assigned a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $71.00.
ANI Pharmaceuticals (ANIP) opened at $57.94 on Tuesday. ANI Pharmaceuticals has a twelve month low of $42.23 and a twelve month high of $74.70. The company has a current ratio of 3.45, a quick ratio of 2.39 and a debt-to-equity ratio of 0.83. The stock has a market cap of $674.13, a PE ratio of 91.97 and a beta of 2.79.
COPYRIGHT VIOLATION WARNING: This news story was first reported by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of international copyright & trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2018/02/22/ani-pharmaceuticals-anip-rating-lowered-to-c-at-thestreet.html.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc is an integrated specialty pharmaceutical company. The Company is engaged in developing, manufacturing and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, anti-cancer (oncolytics), hormones and steroids, and complex formulations.
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.